BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Remicade infliximab regulatory update

Johnson & Johnson's Centocor Ortho Biotech Inc unit submitted an sBLA to FDA to expand the label for Remicade infliximab to include treatment of moderate to severe active ulcerative...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >